Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
3 hedge funds and large institutions have $1.03M invested in Direxion mRNA ETF in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0% less capital invested
Capital invested by funds: $1.03M → $1.03M (-$3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$16.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $363K | +$11.3K | +753 | +3% |
|
2
Bank of America
Charlotte,
North Carolina
| $339K | – | – | – |
|
|
3
Citigroup
New York
| $324K | -$16.5K | -1,100 | -4% |
|
MSGR Hedge Fund Activity: Q3 2022 in Review
3 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q3 2022, worth a combined $1.03M — down 0.29% from $1.03M a quarter earlier.
Fund positioning in MSGR was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $11.3K. The largest seller was Citigroup, cutting an estimated $16.5K.
- 3 institutional investors held Direxion mRNA ETF (MSGR) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.03M of Direxion mRNA ETF stock for Q3 2022, down 0.29% quarter-over-quarter.
- 0 funds opened new Direxion mRNA ETF positions in Q3 2022 and 0 closed out.
- The largest Direxion mRNA ETF buyer in Q3 2022 was UBS Group, an estimated $11.3K added.
- The largest Direxion mRNA ETF seller in Q3 2022 was Citigroup, an estimated $16.5K sold.
Based on aggregated 13F filings for Q3 2022.